Celldex Therapeutics | CLDX - Selling And Administration Expenses

Stock Price
33.20
Daily Change
0.79 2.44%
Monthly
8.04%
Yearly
102.32%
Q2 Forecast
30.13

Celldex Therapeutics reported $7.84M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Agenus USD 10.56M 13.04M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Celldex Therapeutics USD 7.84M 1.21M Dec/2025
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Northwest Biotherapeutics USD 7.07M 1.06M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Roche Holding CHF 7.28B 3.99B Dec/2025